A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib
Ibrutinib (IBR) is an oral anticancer medication that inhibits Bruton tyrosine kinase irreversibly. Due to the high risk of adverse effects and its pharmacokinetic variability, the safe and effective use of IBR is expected to be facilitated by precision dosing. Delivering suitable clinical laborator...
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
MDPI AG
2022-07-01
|
| Collection: | Molecules |
| Sujets: | |
| Accès en ligne: | https://www.mdpi.com/1420-3049/27/15/4766 |